NCT04183413 is a NA clinical trial of DSD in Diabetes Mellitus, sponsored by University Hospital Heidelberg.

Who is sponsoring NCT04183413?

NCT04183413 is sponsored by University Hospital Heidelberg.

What drugs are being tested in NCT04183413?

Interventions in NCT04183413: DSD, CDP.

What condition does NCT04183413 study?

NCT04183413 studies Diabetes Mellitus, Hypertension.

Is NCT04183413 still recruiting?

NCT04183413 is currently completed. Last updated 31 October 2024.

Last reviewed 2024-10-31 · How we verify

NCT04183413

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Strengthening Primary Healthcare Delivery for Diabetes and Hypertension in Eswatini

Completed NA Last updated 31 October 2024

What this trial tests

NA trial testing DSD in Diabetes Mellitus in 3,500 participants. Completed in 31 December 2023.

Timeline

1 November 2021

Primary endpoint
5 December 2023

31 December 2023

Quick facts

Lead sponsor	University Hospital Heidelberg
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	3,500
Start date	1 November 2021
Primary completion	5 December 2023
Estimated completion	31 December 2023
Sites	1 location across Eswatini

Drugs / interventions tested

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →
Hypertension — all drugs for Hypertension →

Sponsor

University Hospital Heidelberg

Who can join

40 and older, any sex, with Diabetes Mellitus or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The WHO-PEN@Scale project is a three-arm cluster-randomized trial that is investigating the population-level effects of a healthcare reform in Eswatini, which aims to strengthen primary care for diabetes and hypertension. Prior to the reform, healthcare for diabetes and hypertension was mostly provided through physician-led teams in hospital outpatient departments. The healthcare reform aims to strengthen the provision of nurse-led care for diabetes and hypertension in primary healthcare facilities and community health worker-led care for these conditions in the facilities' catchment areas. The reform will broadly be guided by the World Health Organization's "Package of Essential Noncommunicable Disease Interventions for Primary Health Care in Low-Resource Settings" (WHO-PEN). The trial will take place at 84 clusters (a primary healthcare facility and its catchment area) across the country.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Strengthening primary care for diabetes and hypertension in Eswatini: study protocol for a nationwide cluster-randomized controlled trial.
Theilmann M, Ginindza N, Myeni J, Dlamini S, et al · · 2023 · cited 3× · PMID 36949485 · DOI 10.1186/s13063-023-07096-4
Human and financial resource needs for universal access to WHO-PEN interventions for diabetes and hypertension care in Eswatini: results from a time-and-motion and bottom-up costing study.
Harkare HV, Osetinsky B, Ginindza N, Cindzi BT, et al · · 2024 · cited 1× · PMID 38802811 · DOI 10.1186/s12960-024-00913-0
Implementation of WHO-PEN interventions in Eswatini: an assessment of health equity and out-of-pocket expenditure for diabetes and hypertension care.
Harkare HV, Ginindza N, Stehr L, Osetinsky B, et al · · 2026 · PMID 41888803 · DOI 10.1186/s12939-026-02829-8

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other University Hospital Heidelberg trials

Trials by the same sponsor.

NCT07388147 — Exercise Therapy for Multiple Myeloma Patients · NA · not yet recruiting
NCT07348874 — Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany · not yet recruiting
NCT07181928 — Is Mentalization-based Therapy More Effective Than Treatment-as-usual for Adolescents With Dissocial Disorders? · NA · not yet recruiting
NCT06954623 — Partial Breast Re-irradiation for Breast Cancer · NA · recruiting
NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04183413 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Heidelberg
Last refreshed: 31 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04183413.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing